Breaking News Instant updates and real-time market news.

TEVA

Teva

$46.30

0.29 (0.63%)

, AGN

Allergan

$229.76

-0.55 (-0.24%)

09:58
10/03/16
10/03
09:58
10/03/16
09:58

Teva completes acquisition of Anda from Allergan

Teva Pharmaceutical (TEVA) announced that it has completed its acquisition of Anda, Inc., a distributor of generic pharmaceuticals in the U.S., from Allergan (AGN). Teva currently has over 300 product registrations pending FDA approval and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. "We are pleased that Anda, Inc., one of the leading distributors of generic medicines in the U.S., is now part of Teva. This acquisition reflects our continued view that attractive growth opportunities, both external and organic, exist for our business and for our extensive supply chain network in particular," said Siggi Olafsson, President & CEO of Global Generic Medicines. "This acquisition enables us and our customers to provide more patients throughout the country with access to generic medicines."

TEVA

Teva

$46.30

0.29 (0.63%)

AGN

Allergan

$229.76

-0.55 (-0.24%)

  • 06

    Nov

  • 15

    Nov

TEVA Teva
$46.30

0.29 (0.63%)

09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
09/23/16
LEER
09/23/16
NO CHANGE
LEER
Outperform
Positive data paves way for Teva SD-809 indication, says Leerink
Leerink analyst Jason Gerberry says the AIM-TD study readout clinically de-risks Teva's (TEVA) SD-809 opportunity for tardive dyskinesia, with the investor focus shifting to market size and competitive differentiation versus Neurocrine's (NBIX) valbenazine. The analyst believes Teva's SD-809 is well positioned to compete against valbenazine with an equally efficacious and well tolerated drug. Further, he expects Teva to exit 2017 with a broader label. Gerberry reiterates an Outperform rating on Teva's shares.
09/29/16
OTRG
09/29/16
INITIATION
OTRG
Positive
Teva initiated with a Positive at OTR Global
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Outperform
Teva shares suffering from lack of catalysts, says Wells Fargo
Wells Fargo analyst David Maris attributes the continued slide in Teva (TEVA) shares largely to negative sector news such as the drug pricing debate, fears on generic pricing, and Mylan's (MYL) EpiPen issue, but also thinks the slide has been made worse by Teva's lack of near-term catalysts. Additionally, the ongoing Copaxone generic trial and Teva's recently filed suit against Rimsa's founders over allegedly being misled by the Mexican pharmaceutical company have added to the pressure, Maris noted. Maris acknowledges there may be "no notable catalysts" for the rest of the year for Teva, but he thinks it should be a "robust 2017" for the company and keeps an Outperform rating on the shares.
AGN Allergan
$229.76

-0.55 (-0.24%)

09/21/16
CANT
09/21/16
DOWNGRADE
CANT
Hold
Tobira Therapeutics downgraded to Hold from Buy at Cantor
Cantor analyst Elemer Piros downgraded Tobira (TBRA) after the company agreed to be acquired by Allergan (AGN). Target to $42 from $19.
09/21/16
GABE
09/21/16
NO CHANGE
GABE
Buy
Gabelli questions if Allergan could target Gilead next
Gabelli analyst Kevin Kedra said that "like most" he was surprised at the price paid and the strategic fit of Allergan's (AGN) deal to buy Tobira Therapeutics (TBRA), but wonders if Allergan CEO Brent Saunders is "playing chess while the market is playing checkers" and could be preparing a bid for Gilead (GILD). After Allergan's "very loud statement about its commitment to NASH and liver disease," a deal for Gilead, the leading company in liver disease and "one of the cheapest companies in pharma/biotech," would appear to make more sense, Kedra tells investors, adding that an acquisition of Gilead at a price of $115 per share would be "highly accretive" for Allergan. The analyst keeps a Buy rating on Allergan shares.
09/22/16
BERN
09/22/16
NO CHANGE
BERN
Allergan acquisitions positive, says Bernstein
After Allergan bought two companies with NASH drugs and the stock fell, Bernstein analyst Aaron Gal says the acquisitions were viewed as expensive. Gal says "it makes almost no difference" if the deals were expensive, as the important issue is whether the products succeed. He believes that the market would never penalize Roche or Celgene for similar deals, and he thinks this indicates that Allergan is "misvalued." He says that Allergan is his "high conviction buy" stock and keeps a $335 price target on the shares.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.

TODAY'S FREE FLY STORIES

OXY

Occidental Petroleum

$75.55

0.16 (0.21%)

, HES

Hess Corp.

$52.61

-1.23 (-2.28%)

07:14
01/22/18
01/22
07:14
01/22/18
07:14
Upgrade
Occidental Petroleum, Hess Corp. rating change  »

Occidental Petroleum…

OXY

Occidental Petroleum

$75.55

0.16 (0.21%)

HES

Hess Corp.

$52.61

-1.23 (-2.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 14

    Feb

07:13
01/22/18
01/22
07:13
01/22/18
07:13
General news
Futures lower as government shutdown enters day three »

Stock futures are…

AIG

AIG

$61.55

0.02 (0.03%)

07:12
01/22/18
01/22
07:12
01/22/18
07:12
Hot Stocks
Breaking Hot Stocks news story on AIG 

AIG trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

  • 20

    Feb

  • 21

    Feb

VR

Validus

$46.72

0.81 (1.76%)

07:12
01/22/18
01/22
07:12
01/22/18
07:12
Hot Stocks
Breaking Hot Stocks news story on Validus 

Validus trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

REXR

Rexford Industrial

$28.79

0.47 (1.66%)

07:11
01/22/18
01/22
07:11
01/22/18
07:11
Hot Stocks
Rexford Industrial acquires industrial property for $11.4M, sells one for $11.4M »

Rexford Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$68.88

-0.91 (-1.30%)

, BA

Boeing

$337.73

-2.43 (-0.71%)

07:11
01/22/18
01/22
07:11
01/22/18
07:11
Hot Stocks
Alaska Air names Ray Conner to board »

Alaska Air Group (ALK),…

ALK

Alaska Air

$68.88

-0.91 (-1.30%)

BA

Boeing

$337.73

-2.43 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 31

    Jan

  • 21

    Feb

PCG

PG&E

$44.39

-0.11 (-0.25%)

07:10
01/22/18
01/22
07:10
01/22/18
07:10
Recommendations
PG&E analyst commentary  »

PG&E price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

ENB

Enbridge

$39.39

-0.33 (-0.83%)

, SEP

Spectra Energy Partners

07:10
01/22/18
01/22
07:10
01/22/18
07:10
Hot Stocks
Enbridge, Spectra Energy Partners complete elimination of IDRs »

Enbridge (ENB) and…

ENB

Enbridge

$39.39

-0.33 (-0.83%)

SEP

Spectra Energy Partners

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

OMER

Omeros

$16.70

-0.02 (-0.12%)

07:10
01/22/18
01/22
07:10
01/22/18
07:10
Hot Stocks
Omeros receives positive opinion for OMS721 from EMA »

Omeros Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIX

Edison International

$62.12

0.2 (0.32%)

07:10
01/22/18
01/22
07:10
01/22/18
07:10
Recommendations
Edison International analyst commentary  »

Edison International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWOU

2U

$72.38

1.49 (2.10%)

07:09
01/22/18
01/22
07:09
01/22/18
07:09
Hot Stocks
2U and WeWork partner in online graduate program expansion »

2U and WeWork Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NQ

NQ Mobile

$3.82

-0.07 (-1.80%)

07:07
01/22/18
01/22
07:07
01/22/18
07:07
Hot Stocks
NQ Mobile proposes to rebrand, change name to "Link Motion Inc." »

NQ Mobile announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$175.95

-6.15 (-3.38%)

07:07
01/22/18
01/22
07:07
01/22/18
07:07
Technical Analysis
Technical Take: bluebird bio moves higher »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

OPB

Opus Bank

$28.70

0.05 (0.17%)

07:07
01/22/18
01/22
07:07
01/22/18
07:07
Earnings
Opus Bank reports Q4 EPS including items 3c, consensus 38c »

Reports net income of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CQH

Cheniere Energy Partners LP

$28.22

0.22 (0.79%)

, CQP

Cheniere Energy Partners

$30.48

0.2 (0.66%)

07:06
01/22/18
01/22
07:06
01/22/18
07:06
Conference/Events
Morgan Stanley to hold a tour »

Annual Morgan Stanley…

CQH

Cheniere Energy Partners LP

$28.22

0.22 (0.79%)

CQP

Cheniere Energy Partners

$30.48

0.2 (0.66%)

ENLC

EnLink Midstream

$18.75

0.25 (1.35%)

ENLK

EnLink Midstream Partners

$17.45

0.37 (2.17%)

EPD

Enterprise Products

$28.66

0.36 (1.27%)

NBLX

Noble Midstream

$55.10

-0.48 (-0.86%)

PAA

Plains All American

$22.49

-0.09 (-0.40%)

SHLX

Shell Midstream

$30.13

-0.03 (-0.10%)

TRGP

Targa Resources

$50.73

0.04 (0.08%)

WES

Western Gas Partners

$52.31

0.34 (0.65%)

WGP

Western Gas Equity

$40.42

0.5 (1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 07

    Feb

  • 16

    Feb

  • 20

    Feb

REGN

Regeneron

$371.53

0.25 (0.07%)

, SNY

Sanofi

$44.60

0.09 (0.20%)

07:06
01/22/18
01/22
07:06
01/22/18
07:06
Hot Stocks
Regeneron reports approval of Dupixent in Japan for atopic dermatitis »

Regeneron (REGN)…

REGN

Regeneron

$371.53

0.25 (0.07%)

SNY

Sanofi

$44.60

0.09 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 02

    May

SLB

Schlumberger

$76.42

0.05 (0.07%)

07:06
01/22/18
01/22
07:06
01/22/18
07:06
Recommendations
Schlumberger analyst commentary  »

Schlumberger price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTNP

Titan Pharmaceuticals

$1.28

0.025 (2.00%)

, BBRX

Braeburn Pharmaceuticals

07:06
01/22/18
01/22
07:06
01/22/18
07:06
Hot Stocks
Titan Pharmaceuticals discussing U.S. Probuphine commercialization with Braeburn »

Titan Pharmaceuticals…

TTNP

Titan Pharmaceuticals

$1.28

0.025 (2.00%)

BBRX

Braeburn Pharmaceuticals

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$54.02

2.42 (4.69%)

, MMM

3M

$248.18

2.27 (0.92%)

07:05
01/22/18
01/22
07:05
01/22/18
07:05
Conference/Events
ASHRAE and AHRI to co-host an expo »

The American Society of…

CC

Chemours

$54.02

2.42 (4.69%)

MMM

3M

$248.18

2.27 (0.92%)

ABB

ABB

$28.01

0.03 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 15

    Feb

07:05
01/22/18
01/22
07:05
01/22/18
07:05
General news
Oil Action: WTI benchmark futures are fractionally lower »

Oil Action: WTI benchmark…

ACBFF

Aurora Cannabis

$10.77

0.302 (2.89%)

07:05
01/22/18
01/22
07:05
01/22/18
07:05
Hot Stocks
CanniMed announces continuation of discussions with Aurora Cannabis »

CanniMed Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNX

Athenex

$17.33

0.12 (0.70%)

07:04
01/22/18
01/22
07:04
01/22/18
07:04
Hot Stocks
Athenex announces results of first cohort of Phase 1b clinical trial of Oraxol »

Athenex announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEVB

Level Brands

$5.10

-0.0385 (-0.75%)

07:03
01/22/18
01/22
07:03
01/22/18
07:03
Hot Stocks
Level Brands, Kathy Ireland announce extension of Isodiol license agreement »

Kathy Ireland, Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABAX

Abaxis

$61.16

0.35 (0.58%)

07:03
01/22/18
01/22
07:03
01/22/18
07:03
Hot Stocks
Abaxis granted USDA Approval for new VetScan FLEX4 Rapid Test »

Abaxis' new VetScan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

QURE

uniQure

$17.99

-0.01 (-0.06%)

07:03
01/22/18
01/22
07:03
01/22/18
07:03
Hot Stocks
uniQure receives OMPD in EU for AMT-130 »

uniQure announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.